

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Thursday 31 January 2019

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
ENTITLEMENT OFFER TO RAISE UP TO \$11.45 MILLION**

Genera Biosystems Limited (**Company**) announces a non-renounceable entitlement offer of fully paid ordinary shares (**Entitlement Offer**). A Prospectus setting out the terms and conditions of the Entitlement Offer was lodged with ASX Limited (**ASX**) on 31 January 2019 (**Prospectus**) and will be sent to all eligible shareholders together with a personalised Entitlement and Acceptance Form on Monday, 11 February 2019.

The new shares to be issued pursuant to the Entitlement Offer will rank equally with the Company's existing fully paid ordinary shares.

The Entitlement Offer is only open to eligible shareholders, being shareholders whose registered address is in Australia or New Zealand at 7.00pm (AEDT) on Wednesday, 6 February 2019 (**Record Date**).

The Company has determined that it would be unreasonable to make offers under the Entitlement Offer to all shareholders with addresses outside of Australia or New Zealand (**Ineligible Shareholders**) having regard to the Company's current shareholding and the costs of complying with legal and regulatory requirements in those jurisdictions. Accordingly, the Entitlement Offer is not being extended to Ineligible Shareholders. Any entitlements to such shares will lapse and the relevant shares will form part of the additional shares and shortfall under the Entitlement Offer.

Funds raised under the Entitlement Offer may be used to reduce, in part or in full the Company's Series B Debt and up to \$275,000 of the Company's Subordinated Mezzanine Debt. These debt repayments shall strengthen Genera's financial position and support the commercial roll-out of Genera's valuable AmpaSand® test menu running on the new instrumentation system. Funds raised will also cover costs of the Offer (estimated at ~\$162,500) and for working capital requirements.

Details of the Entitlement Offer are as follows:

Type of issue	Pro-rata non-renounceable entitlement offer of fully paid ordinary shares (Shares) of 4 Shares for every 5 Shares held as at the Record Date.
Issue price	\$0.13 (13 cents) per Share.
Number of shares to be issued	Up to 88,049,453 Shares.
Amount to be raised	Up to \$11,446,428

Rights trading	Rights cannot be traded or sold.
Top-Up Shares	Eligible shareholders can apply for Top-Up Shares in excess of their Entitlement. Top-Up Shares will be allocated in accordance with the allocation policy set out in the Prospectus. Any entitlement and additional Shares not taken by eligible shareholders will form part of the shortfall. The directors of the Company reserve the right to place the shortfall Shares at their absolute discretion.
Listing	The Company has applied to ASX for quotation of the Shares.

Key indicative dates*

Announcement of Offer	31 January 2019
Lodgement of Prospectus and Appendix 3B with ASX	31 January 2019
Notice sent to shareholders	4 February 2019
Ex Date	5 February 2019
Record Date for determining entitlements	6 February 2019
Prospectus despatched to eligible shareholders and Company announces despatch has been completed	11 February 2019
Closing Date	1 March 2019
Securities quoted on a deferred settlement basis	4 March 2019
ASX notified of under subscriptions	6 March 2019
Issue date	8 March 2019

**The above timetable is indicative only and subject to change. Subject to the ASX Listing Rules, the directors of the Company reserve the right to vary these dates, including the Closing Date, without notice. The directors may extend the period of the Entitlement Offer or bring forward the Closing Date at their discretion.*

Actions required by Eligible Shareholders

To take up all of your rights to subscribe for shares pursuant to the Prospectus (**Entitlement**), you must ensure that your application money for your Entitlement is received by the share registry Computershare no later than 5.00pm (AEDT) on Friday, 1 March 2019, as outlined in your personalised Entitlement and Acceptance Form.

If you only wish to accept part of your Entitlement, you must ensure that your application money for the Entitlements you wish to take up is received by the share registry Computershare no later than 5.00pm (AEDT) on Friday, 1 March 2019, as outlined in your personalised Entitlement and Acceptance Form.

Eligible Shareholders will also be given the opportunity to apply for additional shares above their Entitlement (**Top-Up Shares**). The allocation of any Top-Up Shares will be subject to the Company's discretion and limited to the extent that there are sufficient new shares from shareholders who did not take up their Entitlement.

You are not obliged to take up your Entitlement. However, if you do not take up your Entitlement, your existing interest in the Company will be diluted.

Full details of the terms and conditions of the Entitlement Offer are contained in the Prospectus which is available on the ASX website www.asx.com.au by searching under the ASX Code "GBI."

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited ("GBI") is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera's single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera's development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in 2019, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2020.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera's proprietary ARTG listed and CE-IVD marked QPlots automated analytical and reporting software that is compatible with most Laboratory Information Management Systems ('LIMS'). All the components of the Genera MDx system, including AmpaSand® and QPlots, have been optimized to run on Beckman Coulter's innovative CytoFLEX™ flow cytometry system.

¹ All 'plate based' Real Time PCR platforms can 'multiplex' up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera's AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera's AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.